Alnylam Pharmaceuticals Inc (LTS:0HD2)
$ 215.17 -4.99 (-2.27%) Market Cap: 29.33 Bil Enterprise Value: 27.29 Bil PE Ratio: 40.74 PB Ratio: 21.65 GF Score: 69/100

Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2023 / 12:00PM GMT
Release Date Price: $184.1 (-1.65%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. Welcome to Barclays Global Healthcare Conference. Today is the last day, and I hope everyone had a very productive meetings -- all having additional productive meetings. It is my great pleasure to introduce today's first presenting company, Alnylam. With us today, we have Jeff Poulton, Chief Financial Officer; also Eric Green, SVP, Head of Development Profiles. Thank you for coming to our conference.

Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP

Thank you. Thanks to Barclays for having us. It's always nice to be in Miami in this time of year.

Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Yes, certainly better than Boston.

Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP

Much better.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot